FLOURISH & THRIVE Trial: Real-World Effectiveness of Digital Health Programs Combined with GLP-1 Therapies for Weight Management

References

1. 1.Australian Bureau of Statistics. (2023). National Health Survey: First Results, 2022. Australian Bureau of Statistics. https://www.abs.gov.au/statistics/health/health-conditions-and-risks/national-health-survey-first-results/2022
2. 2.Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
3. 3.Kroenke, K., Strine, T. W., Spitzer, R. L., Williams, J. B., Berry, J. T., & Mokdad, A. H. (2009). The PHQ-8 as a measure of current depression in the general population. Journal of Affective Disorders, 114(1-3), 163-173. https://doi.org/10.1016/j.jad.2008.06.026
4. 4.Michie, S., Yardley, L., West, R., Patrick, K., & Greaves, F. (2017). Developing and evaluating digital interventions to promote behavior change in health and health care: Recommendations resulting from an international workshop. Journal of Medical Internet Research, 19(6), e7218. https://doi.org/10.2196/jmir.7218
5. 5.Noom Inc. (2024). GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH & THRIVE Cohort Study. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07588984
6. 6.Pagoto, S., Waring, M. E., May, C. N., Ding, E. Y., Kunz, W. H., Hayes, R., & Oleski, J. L. (2016). Adapting behavioral interventions for social media delivery. Journal of Medical Internet Research, 18(1), e5086. https://doi.org/10.2196/jmir.5086
7. 7.Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., Gronning, M. O., Hovingh, G. K., Holst, A. G., Ravn, H., Lincoff, A. M., & SELECT Trial Investigators. (2022). Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. American Heart Journal, 229, 61-69. https://doi.org/10.1016/j.ahj.2020.07.007
8. 8.Therapeutic Goods Administration. (2024). Australian Register of Therapeutic Goods. Australian Government Department of Health. https://www.tga.gov.au/products/medicines/artg
9. 9.Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183